Baldetti L, Melillo F, Moroni F, et al. - To inform P2Y₁₂ inhibitor choice in patients with acute coronary syndromes (ACS), researchers performed a network meta-analysis, signifying the largest evidence to date, with 14 studies including 145,019 patients. This systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The study endpoints were major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction (MI), definite stent thrombosis (ST) and major bleeding at 30-day and 1-year all-cause mortality and MI. At 30-day, the superiority of prasugrel over both clopidogrel and ticagrelor was noted in terms of MACE, all-cause death and definite ST endpoints. In MI endpoint, both prasugrel and ticagrelor were shown to be superior to clopidogrel. Ticagrelor vs clopidogrel afforded reduced all-cause death. Relative to clopidogrel, both prasugrel and ticagrelor brought about a decrease in the occurrence of 1-year all-cause death. Overall, prasugrel demonstrated the highest efficacy in decreasing adverse consequences in ACS patients and had the highest likelihood of being the best P2Y₁₂ inhibitor to decrease hard adverse events both at 30-day as well as 1-year follow-up.